Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

MetaVia Inc. Director's Dealing 2024

Jun 8, 2024

34919_dirs_2024-06-07_f53dd863-fa06-48ad-b737-b6a672f0f087.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NeuroBo Pharmaceuticals, Inc. (NRBO)
CIK: 0001638287
Period of Report: 2024-06-07

Reporting Person: STRICKLAND D GORDON (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-06-07 Common Stock A 5051 Acquired 17552 Direct

Footnotes

F1: Represents a grant of restricted stock units issued to the Reporting Person under the Issuer's 2022 Equity Incentive Plan, which vests on the earlier of June 7, 2025 or the day immediately prior to the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continuing service on the applicable vesting date.

F2: The total number of securities beneficially owned
has been adjusted to reflect the Issuer's completion
of a 1-for-8 reverse stock split on December 20,
2023.